The clinical effects of sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, on anthracycline-induced cardiotoxicity remain unknown. Experimental…
Amaya SwansonMarch 13, 2026
Breast cancer patients often receive cardiotoxic cancer therapy, and have an increased risk of cardiovascular…
Amaya SwansonJanuary 14, 2026
Exercise has been shown to reduce cancer recurrence and death rates in observational studies but…
Amaya SwansonDecember 15, 2025
Antibody drug conjugates (ADC) targeting ERBB2 positive breast cancer have improved outcomes, and may even…
Amaya SwansonNovember 9, 2025
Statins are competitive inhibitors of cholesterol biosynthesis and additional derivatives of the mevalonate pathway. For…
Amaya SwansonOctober 15, 2025
Cancer treatments can lead to cancer therapy–related cardiac dysfunction (CTRCD). Sodium glucose cotransporter-2 inhibitors (SGLT2is)…
Amaya SwansonSeptember 15, 2025
The API-CAT trial studied whether among active cancer patients with venous thromboembolism, treatment with a…
Amaya SwansonAugust 15, 2025
Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can be…
Amaya SwansonMay 12, 2025
In the STOP-CA (Statins to Prevent the Cardiotoxicity From Anthracyclines) trial, atorvastatin preserved the left…
Amaya SwansonApril 15, 2025
